CG
PGNX

Cutler Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cutler Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-149,200
Closed -$66K – 7443
2017
Q1 		$66K Buy
+149,200
New +$1.49M ﹤0.01% 2122
2016
Q4 		– Sell
-4,900
Closed -$1K – 7683
2016
Q3 		$1K Buy
+4,900
New +$29.6K ﹤0.01% 6434

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

Cutler Group's PGNX Position: Q4 2017 in Review

Cutler Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 100 shares.

Cutler Group first reported a position in PGNX in Q4 2015 and held it in 8 quarters. The position peaked at $44K in Q4 2015. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • Cutler Group reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 100 Progenics Pharmaceuticals Inc shares in Q4 2017.
  • Cutler Group first reported a position in Progenics Pharmaceuticals Inc in Q4 2015 and held it in 8 quarters.
  • Cutler Group's Progenics Pharmaceuticals Inc position peaked at $44K in Q4 2015.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.